Drugs / KK2430
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07629726 | Jun 2026 → Apr 2027 expected | hematopoietic and lymphoid cell neoplasm | Kyowa Kirin, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KK2430 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07629726 ↗ |
| Route | Intravenous | “KK2430 administered intravenously” NCT07629726 ↗ |